Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

Table 2

Characteristics of eligible studies on PAD patients meeting inclusion criteria for NMA.

Trial name	Treatment	Reference	Sample	Patients after revascularization	Design	Follow-up (months)
PAD after revascularization: surgical and endovascular
VOYAGER PAD (2020) [14]	RIV 2.5 mg bid+ASA (100 mg)	ASA (100 mg)	6564	100% (recent)	Double blind	Median: 28
PAD after revascularization: surgical
BOA (2000) [17]	Phenprocoumon/Acenocoumarol (INR 3.0-4.5)	ASA (80 mg)	2650	100% (recent)	Open label	Mean: 21
CASPAR (2010) [19]	CLO+ASA (75-100 mg)	ASA (75-100 mg)	851		Double blind	Median: 11.9
Johnson 2002/2004 [23]	Warfarin (INR 1.4-2.8)+ASA (325 mg)	ASA (325 mg)	831		Open label	Mean: 36.6
PAD after revascularization: endovascular
Cassar 2005 [20]	CLO+ASA (75 mg)	ASA (75 mg)	132	100% (recent)	Double blind	1
Li 2013 [29]	CLO+warfarin (INR 1.8-2.5)	CLO	88		Open label	≤12
MIRROR (2012) [24]	CLO+ASA (100 mg)	ASA (100 mg)	80		Double blind	6
Liang 2012 [30]	CLO+warfarin (INR 1.8-2.5)	CLO	56		Open label	≤12
Chronic PAD patients
CAPRIE (1996) [18]	CLO+placebo	ASA (325 mg)	19,185 (PAD: 6452)	Not reported	Double blind	Mean: 22.9
COMPASS (2017) [16]	RIV (2.5 mg bid)+ASA (100 mg)	ASA (100 mg)	27,395 (PAD: 7470)	27.4%	Double blind	Mean: 23
	RIV (5 mg bid)
CHARISMA (2006) [21]	CLO+ASA (75-162 mg)	ASA (75-162 mg)	15,603 (PAD: 3096)	50.6%	Double blind	Median: 28
Eikelboom (2005) [22]	CLO+ASA (100 mg)	ASA (100 mg)	36	58.3%	Double blind	3 weeks
WAVE (2007) [25]	VKA (INR 2.0-3.0)+ASA (81-325 mg)	ASA (81-325 mg)	2161	Not reported	Open label	Mean: 35

AE: adverse event; ALI: acute limb ischemia; ASA: aspirin; bid: twice a day; CLO: clopidogrel; CV: cardiovascular; INR: international normalised ratio; IS: ischemic stroke; MI: myocardial infarction; NMA: network meta-analysis; PAD: peripheral artery disease; pt-yrs: patient-years; RCT: randomised controlled trial; VKA: vitamin K antagonists; treatment was initiated soon after revascularization, not later than 10 days following the procedure.